{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:23Z","timestamp":1793834843974,"version":"4.6.1"},"reference-count":74,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["K23 DK131315"],"award-info":[{"award-number":["K23 DK131315"]}]},{"name":"National Institute of Diabetes","award":["K23 DK131315"],"award-info":[{"award-number":["K23 DK131315"]}]},{"name":"Digestive and Kidney Diseases","award":["K23 DK131315"],"award-info":[{"award-number":["K23 DK131315"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Introduction and Objectives: Onabotulinum toxin A (BTXA) is an effective treatment for refractory idiopathic overactive bladder (iOAB). Given the wide spectrum of patient factors and combination of symptoms, a tailored approach to management is needed. This scoping review assesses injection paradigms for iOAB. Prior studies have established the safety and efficacy of BTXA injections, and this review focuses on exploring variations in injection techniques that may inform more tailored approaches and support future research toward optimizing patient outcomes. Methods: We conducted a systematic literature search. Inclusion criteria included full-text English language and primary research studies assessing outcomes in adults undergoing BTXA for iOAB. Findings are summarized using narrative synthesis. Results: Forty-three articles were identified. Key findings include fewer injections (1\u201310 vs. 20\u201340) maintains efficacy while reducing procedure time, discomfort, and retreatment hesitancy. Durability appears to be lower with suburothelial and bladder base injections and higher with detrusor and bladder body injections, though these may carry an increased risk of urinary retention requiring clean intermittent catheterization. Trigone inclusion appears safe and effective without increased vesicoureteral reflux risk. Conclusions: Study heterogeneity and inconsistent reporting limit strong conclusions. Included injection paradigms demonstrated efficacy, high tolerability, symptom relief, and quality-of-life improvements with few adverse events. Further research is needed to refine optimal injection strategies to enhance patient comfort, maximize efficacy, and minimize adverse events. Future studies should ensure comprehensive data collection to clarify these associations.<\/jats:p>","DOI":"10.3390\/toxins17050211","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:38:37Z","timestamp":1745390317000},"page":"211","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-6207","authenticated-orcid":false,"given":"Ekene","family":"Enemchukwu","sequence":"first","affiliation":[{"name":"Department of Urology, Stanford School of Medicine, Palo Alto, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hodan","family":"Mohamud","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shada","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Department of Urology, Stanford School of Medicine, Palo Alto, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harbour","sequence":"additional","affiliation":[{"name":"Department of Urology, Stanford School of Medicine, Palo Alto, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-8004","authenticated-orcid":false,"given":"Raveen","family":"Syan","sequence":"additional","affiliation":[{"name":"Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-506X","authenticated-orcid":false,"given":"Michael","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Department of Urology, Atrium Health\u2014Carolinas Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Gunamany","sequence":"additional","affiliation":[{"name":"Department of Urology, Stanford School of Medicine, Palo Alto, CA 94304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int. Urogynecol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2005.04.017","article-title":"Female urinary incontinence in the west of Turkey: Prevalence, risk factors and impact on quality of life","volume":"48","author":"Kocak","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/luts.12185","article-title":"Prevalence and Risk Factors of Urinary Incontinence and Overactive Bladder in Japanese Women","volume":"10","author":"Ninomiya","year":"2018","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","article-title":"The Burden of Overactive Bladder on US Public Health","volume":"11","author":"Reynolds","year":"2016","journal-title":"Curr. Bladder Dysfunct. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"Early and Consistent Improvements in Urinary Symptoms and Quality of Life with OnabotulinumtoxinA in Patients with Overactive Bladder and Urinary Incontinence: Results from a Randomized, Placebo-controlled, Phase IV Clinical Trial","volume":"27","author":"McCammon","year":"2021","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"ref_13","unstructured":"(2025, March 10). Bladder Wall\u2014An Overview|ScienceDirect Topics [Internet]. Available online: https:\/\/www.sciencedirect.com\/topics\/immunology-and-microbiology\/bladder-wall."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eururo.2009.12.022","article-title":"Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/nau.25061","article-title":"Interventions to improve tolerability of local anesthetic intradetrusor Botulinum toxin injections: A systematic review","volume":"42","author":"Macpherson","year":"2023","journal-title":"Neurourol. Urodyn."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/nau.25392","article-title":"Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: A scoping review","volume":"43","author":"Kelsey","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijcp.12360","article-title":"Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: Reviewing the procedure","volume":"68","author":"Karsenty","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrurol.2015.193","article-title":"Current and potential urological applications of botulinum toxin A","volume":"12","author":"Jiang","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/nau.22925","article-title":"Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder","volume":"36","author":"Jiang","year":"2017","journal-title":"Neurourol Urodyn."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hsiao, S.M., Lin, H.H., and Kuo, H.C. (2016). Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147137"},{"key":"ref_23","unstructured":"(2025, March 06). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5232lbl.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.uroco.2015.10.010","article-title":"Use of onabotulinum toxin A in patients with idiopathic overactive bladder and a lack of efficacy, intolerance or contraindication with anticholinergics","volume":"27","year":"2018","journal-title":"Rev. Urol. Colomb. Colomb. Urol. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study","volume":"196","author":"Nitti","year":"2016","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.31086\/tjgeri.2019.93","article-title":"Efficacy and Safety of Botulinum Neurotoxin in Geriatric Patients with an Overactive Bladder: A Multicentric Study from Turkey","volume":"22","author":"Ozan","year":"2019","journal-title":"Turk. J. Geriatr."},{"key":"ref_28","first-page":"227","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/SPV.0000000000000200","article-title":"Comparison of Short Term Outcomes of Sacral Nerve Stimulation and Intradetrusor Injection of OnabotulinumtoxinA (Botox) in Women With Refractory Overactive Bladder","volume":"21","author":"Singh","year":"2015","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Schulte-Baukloh, H., Wei\u00df, C., Weinberger, S., Hubatsch, M., Schlomm, T., and Ralla, B. (2022). Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients\u2014Preliminary Results. Toxins, 15.","DOI":"10.3390\/toxins15010030"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/nau.23286","article-title":"Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population","volume":"37","author":"Onem","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1757-5672.2012.00165.x","article-title":"Twelve Months Follow-up of Injection of OnabotulinumtoxinA into Vesical Submucosa for Refractory Non-neurogenic Overactive Bladder","volume":"5","author":"Okamura","year":"2013","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"M\u00fchlst\u00e4dt, S., Mischner, S., Kranz, J., Anheuser, P., Mohammed, N., Steffens, J.A., and Fornara, P. (2018). Quo Vadis Botulinum Toxin: Normative Constraints and Quality of Life for Patients with Idiopathic OAB?. Front. Surg., 5.","DOI":"10.3389\/fsurg.2018.00061"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.25290","article-title":"Efficacy and safety of an alternative onabotulinumtoxinA injection paradigm for refractory overactive bladder","volume":"43","author":"MacDiarmid","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00404-012-2349-8","article-title":"Botox(\u00ae) for idiopathic overactive bladder: Efficacy, duration and safety. Effectiveness of subsequent injection","volume":"286","author":"Granese","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/luts.12321","article-title":"Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: A randomized clinical trial","volume":"13","author":"Elbaset","year":"2021","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol. Urodyn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0974-7796.82170","article-title":"Prospective randomized trial of 100u vs. 200u botox in the treatment of idiopathic overactive bladder","volume":"3","author":"AlTaweel","year":"2011","journal-title":"Urol. Ann."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1590\/S1677-5538.IBJU.2014.0221","article-title":"Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder","volume":"41","author":"Abdelwahab","year":"2015","journal-title":"Int. Braz. J. Urol. Off. J. Braz. Soc. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ou, Y.C., Kao, Y.L., Ho, Y.H., Wu, K.Y., and Kuo, H.C. (2023). Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder-Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes. Toxins, 15.","DOI":"10.3390\/toxins15020095"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/nau.25107","article-title":"Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder","volume":"42","author":"Dengler","year":"2023","journal-title":"Neurourol. Urodyn."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/nau.22780","article-title":"Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study","volume":"35","author":"Liao","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/nau.23095","article-title":"Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: Analysis of an open label extension of a randomized trial (the RELAX study)","volume":"36","author":"Owen","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/0970-1591.40612","article-title":"Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience","volume":"24","author":"Mohanty","year":"2008","journal-title":"Indian J. Urol. J. Urol. Soc. India"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00192-007-0548-9","article-title":"Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: A 2-year follow-up","volume":"19","author":"Kuschel","year":"2008","journal-title":"Int. Urogynecol. J. Pelvic. Floor Dysfunct."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/SPV.0000000000001199","article-title":"Postprocedural Pain Associated with 5 Versus 20 Intradetrusor Injections of onabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial","volume":"28","author":"Chang","year":"2022","journal-title":"Urogynecology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s11255-021-02802-0","article-title":"Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB)","volume":"53","author":"Ton","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00192-023-05685-0","article-title":"Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: A randomized clinical trial","volume":"35","author":"Zdroik","year":"2024","journal-title":"Int. Urogynecol. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Na\u00efve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial","volume":"198","author":"Herschorn","year":"2017","journal-title":"J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0391560318759258","article-title":"Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience","volume":"85","author":"Tamburro","year":"2018","journal-title":"Urol. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.juro.2017.05.068","article-title":"Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder","volume":"198","author":"Ginsberg","year":"2017","journal-title":"J. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.aju.2013.07.003","article-title":"The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty","volume":"11","author":"Moeen","year":"2013","journal-title":"Arab. J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs. Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.eururo.2012.02.043","article-title":"Volume matters: Bladder injections of botulinum toxin type A","volume":"61","author":"Dasgupta","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-410X.1990.tb14893.x","article-title":"Morbidity following cystoscopy: Comparison of flexible and rigid techniques","volume":"66","author":"Denholm","year":"1990","journal-title":"Br. J. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1464-410X.1988.tb04421.x","article-title":"Rigid versus flexible cystoscopy. A controlled trial of patient tolerance","volume":"62","author":"Flannigan","year":"1988","journal-title":"Br. J. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5114\/wiitm.2016.60665","article-title":"Patient comfort during flexible and rigid cystourethroscopy","volume":"11","author":"Krajewski","year":"2016","journal-title":"Wideochirurgia Inne Tech. Maloinwazyjne Videosurgery Miniinvasive Tech."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.urology.2015.01.007","article-title":"Prospective multi-institutional study analyzing pain perception of flexible and rigid cystoscopy in men","volume":"85","author":"Seklehner","year":"2015","journal-title":"Urology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4111\/icu.2017.58.1.48","article-title":"The effect of office based flexible and rigid cystoscopy on pain experience in female patients","volume":"58","author":"Casteleijn","year":"2017","journal-title":"Investig. Clin. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.21037\/apm-21-316","article-title":"Does office-based flexible cystoscopy provide better pain perception than rigid cystoscopy: A systematic review and meta-analysis","volume":"10","author":"Feng","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e13853","DOI":"10.1111\/ijcp.13853","article-title":"Comparison of pain, quality of life, lower urinary tract symptoms and sexual function between flexible and rigid cystoscopy in follow-up male patients with non muscle invasive bladder cancer: A randomized controlled cross section single blind study","volume":"75","author":"Ucer","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_68","first-page":"135","article-title":"Flexible and rigid cystoscopy in women","volume":"13","author":"Gee","year":"2009","journal-title":"J. Soc. Laparoendosc. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","article-title":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review","volume":"7","author":"Abrar","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2019.12.001","article-title":"Onabotulinumtoxina Re-Injection for Refractory Detrusor Overactivity Using 3-4 Injection Sites: Results of a Pilot Study","volume":"137","author":"Bonillo","year":"2020","journal-title":"Urology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/nau.23052","article-title":"Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity","volume":"36","author":"Avallone","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/JU.0000000000002800","article-title":"Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence","volume":"208","author":"Chermansky","year":"2022","journal-title":"J. Urol."},{"key":"ref_73","unstructured":"(2025, March 06). Impact of Technique on Outcomes of Botulinum Toxin Injection for Idiopathic Overactive Bladder\u2014American Urological Association [Internet]. [Cited 6 March 2025]. Available online: https:\/\/auanews.net\/issues\/articles\/2022\/february-2022\/impact-of-technique-on-outcomes-of-botulinum-toxin-injection-for-idiopathic-overactive-bladder."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/5\/211\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:19:52Z","timestamp":1760030392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/5\/211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":74,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["toxins17050211"],"URL":"https:\/\/doi.org\/10.3390\/toxins17050211","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}